Health & wellness
    Next Score View the next score

    FDA approves first immunotherapy drug to treat breast cancer

    The Food & Drug Administration campus in Silver Spring, Md.
    Andrew Harnik/AP/File/2015
    The Food & Drug Administration campus in Silver Spring, Md.

    The U.S. Food and Drug Administration has approved the first immunotherapy drug for breast cancer.

    Swiss drugmaker Roche’s Tecentriq was OK’d Friday for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. It’s to be given with chemotherapy, the standard treatment.

    Mount Sinai breast cancer specialist Dr. Amy Tiersten in New York called it ‘‘tremendously exciting news.’’


    Approved for two other cancers, Tecentriq works by boosting the immune system’s ability to spot and kill cancer cells.

    Get The Weekender in your inbox:
    The Globe's top picks for what to see and do each weekend, in Boston and beyond.
    Thank you for signing up! Sign up for more newsletters here

    In a study of 900 women, the benefits were modest. Those who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone. The combo caused nerve pain, nausea and other side effects.

    Tecentriq costs about $13,400 per month.